NSCLC Connect
  • Saved

5yr

Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy - PubMed

Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33712445/

doi: 10.1136/jitc-2020-001966. 1 Laboratory of Experimental Pathology, GIGA-Cancer, University of Liege, Liege, Belgium. 2 Laboratory of Immunophysiology, GIGA-I3, University of Liege, Liege, Belgium. 3 Faculty of Veterinary Medicine, University of...

  • Saved

5yr

Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy - PubMed

Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33718183/

doi: 10.3389/fonc.2021.621992. 1 Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China. 2 Suzhou Key Laboratory for Respiratory Diseases, Suzhou, China. 3 Department...

  • Saved

5yr

First-Line EGFR-TKIs Treatment in Stage I Non-Small-Cell Lung Cancer Patients Harboring EGFR Gene Mutations with Postoperative Intrapulmonary Recurrence - PubMed

First-Line EGFR-TKIs Treatment in Stage I Non-Small-Cell Lung Cancer Patients Harboring EGFR Gene Mutations with Postoperative Intrapulmonary Recurrence - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33628055/

Background: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is an effective treatment for advanced lung cancer harboring EGFR gene mutations, and has improved progression-free survival in several...

  • Saved

5yr

Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study - PubMed

Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33527756/

Among metastatic NSCLC patients with PD-L1 expression ≥50% receiving first-line pembrolizumab, current/former smokers experienced improved PFS and OS. On the contrary, worse outcomes were reported among current/former smokers receiving first-line...

  • Saved

5yr

Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

Source : https://clincancerres.aacrjournals.org/content/27/3/704

Purpose: Clonal architecture is fundamental for the understanding of cancer biology and therapy; however, multiregional sampling in advanced-stage cancers is not always applicable. This prospective clinical trial was to investigate...